Connect with us

Healthcare

Got Neuropathy, Try a Cannabis Inhaler For the Best Pain Relief Says New Israeli Study

Published

on

The best relief for neuropathy patients was aerosolized cannabis says new medical study?

Israeli Study Finds That Aerosolized Cannabis Is Beneficial For Neuropathy Patients

Neuropathy, also known as nerve damage, can occur from several conditions such as diabetes, cancer, and HIV. It refers to a group of conditions all associated with damaged peripheral nerves and the corresponding symptoms of this issue.

The symptoms of neuropathy can vary depending on its cause, though they generally include a permanent or temporary numbness, high sensitivity to touch, prickling or tingling sensations, paralysis, muscle weakness, impairment to sexual function, and many others. Neuropathy may be treatable depending on how severe it is, though treatments are focused on helping nerves regenerate or recover. Depending on the case, neuropathy may be reversible but other times it isn’t, and it can be notoriously difficult and painful to treat. Patients are often left struggling with chronic pain and uncomfortable tingling.

However, finding effective treatment is critical because this condition robs people of living a normal life.

How Cannabis Can Help

There is increasing evidence that cannabis in various forms can be successful in greatly reducing the symptoms of neuropathy. The latest study has been conducted by Israeli researchers in Haifa, who sought out to assess how aerosolized cannabis delivered through a novel selective dose inhaler worked among patients with chronic pain and neuropathy. The patients took an average of 1.5 mg delta 9 THC for several months.

The researchers found that this treatment was beneficial in reducing pain while also improving quality of life. “Medical cannabis treatment with the Syqe Inhaler demonstrated overall long-term pain reductions, quality of life improvements, and opioid-sparing effects in a cohort of patients with chronic pain, using just a fraction of the amount of MC [medical cannabis] compared with other modes of delivery by inhalation. These outcomes were accompanied by a lower rate of AEs [adverse events] and almost no AE reports during a long-term steady-state follow-up. Additional follow-ups in a larger population is warranted to corroborate our findings,” the authors concluded.

Syqe Medical is an Israeli medical company that is responsible for developing the first selective-dose pharmaceutical-grade inhaler for plant medicine in the world.

Another recent study which was published in the Annals of Internal Medicine journal investigated the efficacy of cannabis-related products for chronic pain. Researchers from the Oregon Health and Science University used FDA-approved synthetic cannabis products containing 100% THC: dronabinol and nabilone. They also tested a product called nabiximols, which is a sublingual spray containing equal ratios of THC and CBD, which has had some success in treating neuropathic pain, though it isn’t available in the United States yet.

In another study from 2018, published in the American Journal of Neurology, researchers focused on radicular pain, a form of nerve pain that affects the spine and the legs. They also analyzed the impact of THC on radicular pain on a cohort of 15 men suffering from chronic radicular nerve pain. Women were not included in the study since pain sensitivity in females fluctuates around the time of their menstruation. All men reported medium to high pain levels for more than 6 months.

They were first given 15mg of THC oil on the first visit, which was taken sublingually while 6 were administered with placebo oil. After a week, they returned for a second visit then those who were given placebo were then given THC, and vice versa. The researchers found that THC was effective in reducing pain when compared with the placebo. Pain levels were rated at 53 on average before taking THC which was reduced to an average of 35 after THC, while those in the placebo rated it at 43.

“Pain is a complex experience that involves both the senses and emotions,” explains study’s author Haggai Sharon, MD, of the Tel Aviv Medical Center’s Sagol Brain Institute. “Our study results link pain relief from THC with a reduction in the connections between areas of the brain otherwise heavily connected, suggesting that THC may alleviate pain by disrupting signals between these pain processing pathways.”

“Interestingly, our results also show that the more connected the areas of the brain that process emotion and sensory prior to treatment, the greater the pain relief experienced when taking THC,” Sharon explains. “Larger studies are needed to confirm our findings.”

Cannabidiol (CBD) may also be beneficial for neuropathy. A 2021 study conducted by Pure Green Pharmaceuticals Inc. analyzed the effect of water-soluble CBD sublingual tablets among diabetic patients who had moderate to severe neuropathic pain. These 54 patients suffered from painful peripheral neuropathy on their feet, and they were randomly given either the Pure Green tablets with 20mg of CBD, or a placebo, which they were to take daily for 28 days.

They found that the patients who were given the CBD tablets reported significant reductions in pain levels, compared to the pain group. Additionally, those given CBD also reported improvements in quality of life as well as reductions in anxiety and improvements in sleep quality.

“Achieving clinical and statistical pain relief for these patients in just a few weeks is very gratifying and frankly unexpected. Interestingly, the results of this placebo-controlled trial mirrored those of Pure Green Pharmaceuticals’ open-label pDPN trial where both studies revealed a significant drop in pain scores by approximately 50 percent. Patient safety always comes first and was our primary marker. There were no adverse events in either clinical trial to patients on treatment medication,” explained Dr. Debra Kimless, Pure Green’s Chief Medical Officer and a Board-Certified anesthesiologist.

“A collaborative drug development meeting with the FDA set us on this path and we look forward to returning to FDA and share this data. FDA is keen to relieve patients suffering in this very large patient population, especially since COVID-19 appears to have increased the number of diabetic patients,” added Stephen Goldner, Pure Green Pharmaceuticals CEO, and an FDA expert.

Conclusion

With these promising results, patients with neuropathy are encouraged to speak to their doctors on the possibility of adding cannabis products to their treatment plans.

Source: https://cannabis.net/blog/medical/got-neuropathy-try-a-cannabis-inhaler-for-the-best-pain-relief-says-new-israeli-study

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis & Policy

Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals

Published

on

By

The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.

During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.

Court Questions Wide Gap Between Retail Price and MRP

The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.

The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.

Concerns Over In-House Hospital Pharmacies

The court also examined the purchasing practices of corporate hospitals.

According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.

The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.

Impact on Government Health Schemes

The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.

Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.

The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.

Government Seeks Time to Examine the Issue

Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.

The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.

The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.

Court’s Earlier Warning on Medicine Pricing

The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.

The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.

The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.

What Happens Next?

The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.

The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.

Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.

Continue Reading

Economic Fraud

Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye

Published

on

By

U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.

The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.

International Manhunt Ends with Arrest in Türkiye

According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.

Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.

A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.

Alleged Scheme Targeted Medicare Reimbursement System

Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.

Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.

While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.

Federal Agencies Expand Investigation

The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.

Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.

Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.

Healthcare Fraud Remains a Major Concern

Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.

Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.

Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.

Growing Importance of Global Law Enforcement Cooperation

The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.

Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.

Legal Proceedings Ahead

The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.

The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.

For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.

Continue Reading

Cyber Crime

Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024

Published

on

By

Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.

The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.

Healthcare Professionals Under Growing Cyber Threat

Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.

Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.

More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.

Investment Scams Responsible for Major Financial Losses

According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.

Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.

Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.

Authorities Stress Importance of Rapid Reporting

The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.

Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.

The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.

Medical Associations Join Awareness Drive

Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.

Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.

As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News